765 results about "Glucose lowering" patented technology

Reducing the digestion of digestible carbohydrates in a digestible carbohydrate-based material, and reducing the absorption of the digestion product(s) of digestible carbohydrates (that is, simple sugars) within the small intestine. The undigested digestible carbohydrate and the unabsorbed digestion products pass through the small intestines and into the colon, where they are fermented. In effect, the food materials made by practicing the present invention cause a controlled amount of digestible carbohydrate to by-pass the small intestine, resulting in the fermentation of digestible carbohydrates in the colon. The invention also provides for processing of a digestible carbohydrate-based ingredient with a non-digestible food film material, to form a reduced digestible carbohydrate food having a protective food film network, which can inhibit or prevent digestion of the digestible carbohydrate. The present invention also provides for processing of a digestible carbohydrate-based ingredient with a non-digestible food film material, to provide a resulting reduced digestible carbohydrate food containing a viscosity-building component that contributes to the formation of a viscous intestinal chyme that can inhibit or prevent digestion of the digestible carbohydrate and can inhibit adsorption of digestion products of digestible carbohydrates in the small intestine.

Endoplasmic reticulum stress has been found to be associated with obesity. Therefore, agents that reduce or prevent ER stress may be used to treat diseases associated with obesity including peripheral insulin resistance, hypergylcemia, and type 2 diabetes. Two compounds which have been shown to reduce ER stress and to reduce blood glucose levels include 4-phenyl butyric acid (PBA), tauroursodeoxycholic acid (TUDCA), and trimethylamine N-oxide (TMAO). Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide and glycerol. The present invention provides methods of treating a subject suffering from obesity, hyperglycemia, type 2 diabetes, or insulin resistance using ER stress reducers such as PBA, TUDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in ER stressed cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating obesity-associated diseases.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

PCT No. PCT/KR97/00133 Sec. 371 Date May 4, 1999 Sec. 102(e) Date May 4, 1999 PCT Filed Jul. 2, 1997 PCT Pub. No. WO98/00389 PCT Pub. Date Jan. 8, 1998This invention relates to a novel 2-hydroxypropionic acid derivative and its manufacturing method. Based on its mechanism to inhibit the CPT I, 2-hydroxypropionic acid derivative of this invention has blood glucose lowering effects so that the derivative may be effectively used as an antidiabetic agent having remarkable antidiabetic activity and fewer side effects.

Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.

To provide a method of lowering blood glucose levels and a method of treating and preventing diabetes.

A belt-shaped compression strip 1 is fitted around a tightened area near the proximal end of an arm or a leg of a user and is fastened round the area. In this way, a compression pressure of on the order of 150 mmHg is applied to the tightened area to restrict blood flow through limbs receiving the compression pressure. This condition is held for about 15 minutes. During that time a user may keep rest or may do light exercises, which lowers a blood glucose level of the user. This provides treatment for diabetes for a diabetes patient and provides prevention of diabetes for a person who has a risk of developing diabetes.

The invention provides a preparation method and application of physiologically active notoginseng polysaccharide. The method comprises the steps of refining and purifying by applying resin column chromatography, activated carbon and membrane separation and purification technology, and the like, so as to obtain the notoginseng polysaccharide. The notoginseng polysaccharide obtained by the preparation method provided by the invention has the characteristics of low protein, heavy metal and ash contents and stable quality, has the physiological activities of immunity regulation, liver injury protection, blood glucose decrease, tumor resisting and the like, and can be used singly or combined as raw materials for natural medicines and health products. The preparation method of the notoginseng polysaccharide, provided by the invention, is simple to operate, applicable for industrial production and low in cost and reaches the purposes of energy saving and consumption reduction and realizing comprehensive development and sustainable utilization of the rare Chinese traditional medicine, namely, notoginseng.

A method for treating hyperglycemia and/or reducing serum glucose levels in a patient that includes administering to the patient a therapeutically effective amount of an amine polymer is disclosed. In one embodiment, the amine polymer is aliphatic. Examples of polymers useful in an embodiment of the invention include sevelamer hydrogen chloride and colesevelam. The invention includes the use of amine polymers such as a cross-linked polymer characterized by a repeat unit having the formula:

and salts and copolymers thereof, where n is a positive integer and x is zero or an integer between 1 and about 4. Also described is a use, for the manufacture of a medicament, of a polymer that lowers serum glucose.

The invention discloses bolete extracting solution and beverages, belonging to the field of edible fungi beverages. The preparation method of the bolete extracting solution comprises the following steps of: extracting crushed bolete dry powder or fresh bolete slurry in water, then filtering to obtain filtrate, centrifuging the filtrate, and collecting supernate. By utilizing the bolete extracting solution, different flavors of bolete beverages can be prepared. The bolete beverage has rich nutrient components and simultaneously contains a great deal of polysaccharides with the functions of improving body immunity, reducing the blood sugar levels and cholesterol, resisting the ageing, and the like; secondly, the invention is convenient to carry and ready to drink and solves the problem that fresh bolete is difficult to store and transport; the invention can be also used as raw materials of beverages and food processing and prepared into different flavors of beverages; and besides, the invention has simple method, low cost and no environmental pollution.

The invention relates to a solid beverage having an assisted blood glucose lowering function, and a preparation method thereof, wherein the main function components are three or more than three materials selected from kelp or a kelp extract, potassium alginate (low molecular weight potassium alginate), common yam rhizome or a common yam rhizome extract, Chinese wolfberry or a Chinese wolfberry extract, radix puerariae or a radix puerariae extract, mulberry leaf or a mulberry leaf extract, a polygonatum odoratum extract, a bitter gourd extract, the leaf of cyclocarya paliurus and corn stigma, the auxiliary materials comprise one or more than one materials selected from inulin, resistant dextrin, bean powder, tea powder, pumpkin powder, soybean protein powder, barley leaf powder, oat fiber powder, konjac powder and citrus fiber powder, and the flavoring agent is one or a plurality of materials selected from stevioside, xylitol, fructo oligosaccharide, isomaltitol, sucralose, trehalose, matcha powder, and fruit and vegetable powder. The preparation method comprises: 1, crushing, and screening; 2, weighing; 3, carrying out mixing stirring, or carrying out stirring mixing and granulation; and 4, packaging. The solid beverage of the present invention has advantages of significant blood glucose lowering effect, good safety, and no side effect.

The present invention provides a blood glucose-lowering health-care product and the preparation method thereof, wherein the health-care product comprises components with the shares in weight as follows respectively: sealwort (30 to 40 shares), yam (30 to 44 shares), and kudzu root (30 to 38 shares), and the preparation method of the blood glucose-lowering health-care product includes the procedures as follows: a. prepare the raw materials as above based on the weight shares, and then, b. each material is made into fine powder, filtrated and then, c. all raw materials are mixed, weighed, and encapsulated. The health-care product provided by the present invention has reliable health-care effect without any side effect, and has high nutritional value, capability to tonify Qi, improve and adjust the organic immunity, with outstanding effect to lower the blood glucose.

A feungreek extract containing the common saponin of feungreek for preventing and treating diabetes and its chronic complications is prepared through extracting with alcohol, macroreticular adsorption, washing for removing impurities, eluting, concentrating the eluting liquid, and drying.

The invention discloses a processing technique of health thorn tea and processing equipment for health thorn tea, which relate to the technical field of processing of agricultural products. The health thorn tea is made of fresh thorn tea leaves. The processing technique includes cutting, primary fixation, primary spreading and cooling, secondary fixation, secondary spreading and cooling, primary rolling, tertiary spreading and cooling, primary baking, secondary rolling, fourth spreading and cooling, secondary baking, grading and packaging. The processed health thorn tea has the advantages of blood glucose lowering, blood lipid lowering, blood pressure lowering, immunity enhancement, heart rate slowing, coronary flow increasing, anticoagulation, antithrombosis, hypoxia tolerance, mononuclear macrophage functional promotion, radio resistance and the like, and is suitable for middle-aged and aged people and people with hyperlipidemia, hypertension and hyperglycemia. The processing technique and the processing equipment for the health thorn tea can also be used for processing common tea and other types of health tea.

The invention provides a separation and purification method of a human umbilical cord mesenchymal stem cell exosome and an application of the human umbilical cord mesenchymal stem cell exosome, and belongs to the technical field of medicines. The human umbilical cord mesenchymal stem cell exosome provided by the invention is prepared by cultivating human umbilical cord mesenchymal stem cells via aserum-free medium, collecting supernatant liquid, implementing centrifuging as well as ultra-filtration and concentration, transferring a concentrated solution onto a 30% sucrose-heavy water densitypad and implementing further purification through sucrose density centrifuging, so that the human umbilical cord mesenchymal stem cell exosome is obtained. According to the separation and purificationmethod that the human umbilical cord mesenchymal stem cell exosome is obtained through separation and purification, immunoreactivity is effectively reduced, and a controllable dosage when the human umbilical cord mesenchymal stem cell exosome is used is guaranteed. The human umbilical cord mesenchymal stem cell exosome, by improving a degree of activating an insulin signaling pathway of a type IIdiabetes animal model, can inhibit composition and decomposition of hepatic glycogen, so that glucose metabolism homeostasis can be achieved; and meanwhile, the sensitivity of the type II diabetes animal model to insulin and an insulin secretion function of pancreatic [beta] cells can be improved and a blood glucose concentration can be reduced, so that the application of the human umbilical cordmesenchymal stem cell exosome to the preparation of medicines for treating type II diabetes can be achieved.

The invention provides a blood glucose-lowering food containing okra and a preparation method of the blood glucose-lowering food containing okra, wherein the blood glucose-lowering food is characterized by comprising components by weight as follows: 30-60 parts of okra, 15-45 parts of balsam pear and 15-45 parts of Chinese yam. The food uses okra, balsam pear and Chinese yam with higher value as raw materials, and above materials are pure natural plants and contains comprehensive nutrients, trace elements and dietary fibers necessary for human body; the finished product is obtained by mixing and grinding, filtering, drying and sterilizing; the preparation process is simple, the price is cheap, the taste is good, and the effect of lowering blood glucose is obvious; each component plays a role of supplementing each other in lowering blood glucose; adverse reactions caused by long-term consumption can be cancelled out; the applicable group is greatly enlarged; and the finished product used as the food is convenient to eat and has functions of improving microcirculation and improving organism immunity.

The invention relates to the field of traditional Chinese medicines and discloses a traditional Chinese medicinal composition for treating diabetes and a preparation method thereof. The traditional Chinese medicinal composition for treating diabetes is prepared from the following raw materials in part by weight: 12 to 30 parts of astragalus, 3 to 5 parts of vine root, 18 to 30 parts of yam, 9 to 15 parts of anemarrhena asphodeloides bunge, 6 to 12 parts of mongolian snakegourd root, 4 to 6 parts of Chinese magnoliavine fruit and 3 to 5 parts of chicken's gizzardskin. The preparation method of the traditional Chinese medicinal composition comprises: leaching the astragalus, vine root and Chinese magnoliavine fruit with ethanol, filtering extract and collecting filtrate; leaching the yam, anemarrhena asphodeloides bunge and mongolian snakegourd root with water, filtering extract, condensing the filtrate, performing alcohol precipitation, filtering and collecting filtrate; and combining filtrate, drying, crushing, and mixing the crushed product with fine chicken's gizzardskin powder. The traditional Chinese medicinal composition for treating diabetes can relieve the symptoms of polydipsia, polyuria, polyphagia, emaciation, fatigue and weakness of diabetes, reduce blood sugar and treat diabetes of deficiency of Qi-Yin syndrome with urine sugar and blood sugar rise, and has remarkable treatment effect.